The global enzymatic DNA synthesis market size was valued at USD 233.90 million in 2023 and is anticipated to reach around USD 2,454.34 million by 2033, growing at a CAGR of 26.5% from 2024 to 2033.
The enzymatic DNA synthesis (EDS) market represents a significant technological advancement within the synthetic biology and genomics landscape. Unlike traditional phosphoramidite chemical synthesis, EDS utilizes enzymatic reactions to construct DNA sequences with higher fidelity, speed, and environmental safety. This method mimics natural DNA replication and leverages engineered polymerases or template-independent enzymes, unlocking new possibilities for the production of longer, purer, and more functional DNA strands.
The global demand for synthetic DNA is escalating due to its application in emerging areas like cell and gene therapy, vaccine development, diagnostics, agricultural genomics, and DNA data storage. However, chemical synthesis methods face scalability limitations, error accumulation, and environmental concerns from reagent waste. EDS addresses these limitations by offering a greener, faster, and more flexible alternative that aligns with the evolving demands of synthetic biology workflows.
While EDS technology is still in the early commercialization phase, multiple biotech companies and academic labs are actively refining the approach, aiming for high-throughput, automated, and cost-efficient synthesis platforms. Its potential to revolutionize gene synthesis and oligonucleotide production is driving investor interest and attracting collaborations between synthetic biology firms and pharmaceutical giants. As the biotechnology industry pivots toward sustainable and scalable solutions, enzymatic DNA synthesis is positioned to become a cornerstone of next-generation molecular biology manufacturing systems.
Transition from Chemical to Enzymatic Methods: A growing number of companies are phasing out traditional phosphoramidite-based synthesis for enzymatic alternatives.
Automation and Miniaturization of Synthesis Platforms: Microfluidic and benchtop systems are being developed to enable on-demand DNA synthesis in research and clinical settings.
Longer and Error-Free Oligonucleotide Production: EDS allows for the synthesis of longer DNA strands (>300 bases) with significantly fewer errors.
Rising Application in DNA Data Storage: As tech firms explore molecular data storage, EDS is being evaluated for its potential in producing high-integrity storage strands.
Growth of Custom Gene Synthesis Services: Personalized gene constructs for therapeutic and diagnostic use are boosting demand for enzymatic synthesis providers.
Environmentally Friendly DNA Manufacturing: EDS aligns with sustainable biotech initiatives by eliminating toxic solvents and reducing hazardous waste.
Emergence of Academic-Industrial Collaborations: Universities and startups are working together to commercialize novel enzymes and protocols.
Integration with CRISPR and Genome Editing: Faster DNA construct production via EDS is accelerating genome editing research and CRISPR applications.
| Report Attribute | Details |
| Market Size in 2024 | USD 295.88 million |
| Market Size by 2033 | USD 2,454.34 million |
| Growth Rate From 2024 to 2033 |
CAGR of 26.5% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Service, application, end-use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Telesis Bio Inc.; Twist Bioscience Corporation; GenScript Biotech Corp.; Evonetix; Ansa Biotechnologies, Inc.; Camena Bio; Molecular Assemblies; DNA Script; Touchlight; Kern Systems |
One of the most powerful drivers behind the enzymatic DNA synthesis market is the demand for sustainable and scalable DNA synthesis technologies that improve accuracy while reducing environmental and operational costs. Traditional chemical synthesis relies on hazardous organic solvents and generates considerable waste. Additionally, it becomes inefficient and error-prone when synthesizing longer DNA strands, which are increasingly required in synthetic biology, gene therapy, and DNA computing.
In contrast, EDS offers a clean, efficient alternative by using water-based enzymatic reactions, resulting in significantly less toxic byproducts. It also supports longer read lengths and reduced sequence errors, enabling the reliable production of functional genetic constructs. As industries and regulatory bodies push for greener biomanufacturing practices and faster turnaround times, enzymatic synthesis technologies provide an attractive, scalable solution. Companies that can offer plug-and-play EDS systems for automated gene and oligo synthesis will be positioned at the forefront of the industry.
Despite its advantages, the enzymatic DNA synthesis market faces a critical restraint in the form of high costs and limited scalability for commercial-grade production. The enzymes used in EDS—such as terminal deoxynucleotidyl transferase (TdT) and engineered polymerases—are expensive to produce and stabilize. Furthermore, the reagents required for base-by-base synthesis remain costly, particularly when precision incorporation or modified bases are needed.
Additionally, while many EDS platforms have demonstrated feasibility at a laboratory scale, few have successfully transitioned to large-scale, commercial throughput operations. In contrast, chemical synthesis platforms have decades of industrial optimization, supply chain integration, and regulatory familiarity. As a result, widespread adoption of EDS may remain limited until per-base costs decline and production volumes can match those of established platforms.
A significant opportunity for the enzymatic DNA synthesis market lies in the rising need for personalized DNA sequences in precision medicine and therapeutic development. As biopharmaceutical companies increasingly explore custom-engineered constructs for gene therapy, mRNA vaccines, and synthetic biology-based treatments, the demand for fast, accurate, and reliable DNA synthesis is reaching unprecedented levels.
EDS enables on-demand synthesis of therapeutic-grade DNA sequences with higher integrity and fewer impurities, which is especially important in regulated applications. For example, vaccine developers can benefit from rapid synthesis of variant-specific antigens, while gene therapy firms need long, pure sequences for viral vector packaging. By offering automated EDS platforms for decentralized production—potentially even within hospital or clinic labs—companies can create rapid-response solutions tailored to individual patient needs or emerging infectious threats.
Synthetic biology led the application segment, reflecting the field’s rapid expansion and reliance on custom DNA sequences. From engineered microbes for sustainable chemical production to synthetic enzymes and genetic circuits, synthetic biology applications require quick, scalable DNA synthesis workflows. Enzymatic synthesis platforms, with their high adaptability and minimal contamination risks, are emerging as foundational tools in synthetic biology labs and biofoundries.
Vaccine development is emerging as the fastest-growing application, particularly in the post-COVID-19 era. The need to respond quickly to emerging variants has pushed developers toward platforms that can rapidly design, synthesize, and test vaccine candidates. EDS is ideally suited for such a dynamic environment, providing rapid turnarounds and enabling high-fidelity production of antigen-encoding sequences. mRNA vaccine developers, in particular, rely on synthetic DNA templates, and enzymatic methods offer the speed and safety required in this sensitive domain.
Oligonucleotide synthesis dominated the market in 2023, driven by the widespread need for custom primers, probes, and small DNA fragments in research, diagnostics, and sequencing workflows. Oligonucleotides are essential in PCR, qPCR, DNA hybridization, CRISPR, and synthetic gene assembly. Enzymatic DNA synthesis enhances oligonucleotide production by allowing error-free incorporation of specific bases in a highly controlled manner. Furthermore, the ability to synthesize oligos directly in automated desktop systems offers cost savings and turnaround time advantages for labs and biotech startups alike.
Gene synthesis is the fastest-growing service segment, owing to the rising adoption of synthetic biology and engineered therapeutic platforms. Full-length genes, including large or complex constructs, are increasingly being synthesized de novo using enzymatic approaches. With EDS offering higher fidelity, the construction of synthetic operons, plasmids, or expression cassettes becomes more efficient and less error-prone. This is particularly crucial for vaccine development, metabolic engineering, and DNA origami applications, where time-to-market and functional accuracy are paramount. Enzymatic methods reduce dependency on lengthy cloning and correction steps, accelerating innovation cycles.
Biopharmaceutical companies dominate the end-use segment, due to their extensive requirements for synthetic DNA in drug discovery, gene therapy, and vaccine development. These firms seek rapid synthesis of functional genes and regulatory elements that can be scaled for production. Enzymatic DNA synthesis supports these needs by offering longer fragments, lower error rates, and reduced purification steps, helping to accelerate research pipelines and reduce regulatory hurdles.
Academic and research institutes are the fastest-growing end-use category, bolstered by increased funding in genomics, bioengineering, and life sciences. Universities and government research centers are exploring enzymatic synthesis for basic science, genome editing, and environmental DNA applications. These institutions often serve as early adopters, helping to validate and refine new EDS technologies before wider commercialization. As access to enzymatic synthesis becomes more affordable, its adoption is expected to rise sharply across research labs worldwide.
North America held the largest share of the global enzymatic DNA synthesis market in 2024, thanks to its mature biotech ecosystem, leading research institutions, and favorable investment climate. The U.S. is home to pioneering companies in EDS technology such as DNA Script and Molecular Assemblies, alongside major synthetic biology firms like Ginkgo Bioworks and Twist Bioscience. Government agencies, including the NIH and DARPA, have also funded enzymatic synthesis research, recognizing its potential in biosecurity and pandemic response. Moreover, the regulatory infrastructure supports rapid translation of novel DNA technologies into clinical and commercial applications.
Asia-Pacific is the fastest-growing market, fueled by increased biotech investments, expansion of genomic research, and a growing pool of synthetic biology startups. Countries like China, India, South Korea, and Singapore are actively developing national bioeconomy strategies, where DNA synthesis plays a central role. Additionally, APAC governments are supporting DNA manufacturing capacity as part of strategic healthcare independence and innovation initiatives. As local firms adopt or co-develop enzymatic synthesis tools, and with demand rising for custom DNA in agriculture, diagnostics, and therapeutics, the region is poised for strong compound annual growth.
March 2025 – DNA Script launched the next-gen version of its SYNTAX platform, featuring expanded base compatibility and integration with cloud-based sequence management tools.
February 2025 – Molecular Assemblies announced a strategic partnership with a global vaccine developer to provide enzymatically synthesized DNA templates for rapid vaccine prototyping.
January 2025 – Camena Bioscience received a Series B funding round of $35 million to scale its proprietary enzymatic DNA synthesis platform and expand its European market footprint.
December 2024 – Evonetix revealed a new enzymatic protocol incorporated into its desktop DNA printer, aiming for broader adoption in academic and industrial research labs.
November 2024 – GenScript Biotech introduced a hybrid chemical-enzymatic synthesis workflow for long oligonucleotides, reducing costs while improving strand fidelity.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Enzymatic DNA Synthesis market.
By Service
By Application
By End-use
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers